“…Studies so far have largely focused microsatellite discovery efforts on the Roche 454 (454 Life Sciences, a Roche Company, Branford, Connecticut, USA) and Illumina (Illumina, San Diego, California) platforms (Jennings et al, 2011; Zalapa et al, 2012), although Pacific Biosciences (PacBio, Menlo Park, California, USA) (Grohme et al, 2013; Wei et al, 2014) and Ion Torrent (Thermo Fisher Scientific, Waltham, Massachusetts, USA) (Huey et al, 2013; Kameyama and Hirao, 2014) have also been used. Because read length greatly affects the ability to discover microsatellite markers, as longer reads will more likely include the flanking regions needed for primer design (Lepais and Bacles, 2011; Schoebel et al, 2013; Elliott et al, 2014), the 454 sequencing platform was used extensively for microsatellite development (Castoe et al, 2010). On a per-megabase basis, however, 454 is less cost-effective than Illumina (Glenn, 2011; ).…”